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Abstract
Many human adenovirus (Ad) serotypes use the coxsackie B virus-Ad receptor (CAR). Recently, CD46
was suggested to be a receptor of species B Ad serotype 11 (Ad11), Ad14, Ad16, Ad21, Ad35, and
Ad50. Using Sindbis virus-mediated cDNA library expression, we identify here the membrane cofactor
protein CD46 as a surface receptor of species B Ad3. All four major CD46 transcripts and one minor
CD46 transcript expressed in nucleated human cells were isolated. Rodent BHK cells stably expressing
the BC1 form of CD46 bound radiolabeled Ad3 with a dissociation constant of 0.3 nM, identical to that
of CD46-positive HeLa cells expressing twice as many Ad3 binding sites. Pull-down experiments with
recombinant Ad3 fibers and a soluble form of the CD46 extracellular domain linked to the Fc portion of
human immunoglobulin G (CD46ex-Fc) indicated direct interactions of the Ad3 fiber knob with
CD46ex-Fc but not CARex-Fc (Fc-linked extracellular domain of CAR). Ad3 colocalized with cell
surface CD46 in both rodent and human cells at the light and electron microscopy levels. Anti-CD46
antibodies and CD46ex-Fc inhibited Ad3 binding to CD46-expressing BHK cells more than 10-fold and
to human cells 2-fold. In CD46-expressing BHK cells, wild-type Ad3 and a chimeric Ad consisting of
the Ad5 capsid and the Ad3 fiber elicited dose-dependent cytopathic effects and transgene expression,
albeit less efficiently than in human cells. Together, our results show that all of the major splice forms of
CD46 are predominant and functional binding sites of Ad3 on CD46-expressing rodent and human cells
but may not be the sole receptor of species B Ads on human cells. These results have implications for
understanding viral pathogenesis and therapeutic gene delivery.
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Many human adenovirus (Ad) serotypes use the coxsackie B virus-Ad receptor (CAR). Recently, CD46 was
suggested to be a receptor of species B Ad serotype 11 (Ad11), Ad14, Ad16, Ad21, Ad35, and Ad50. Using
Sindbis virus-mediated cDNA library expression, we identify here the membrane cofactor protein CD46 as a
surface receptor of species B Ad3. All four major CD46 transcripts and one minor CD46 transcript expressed
in nucleated human cells were isolated. Rodent BHK cells stably expressing the BC1 form of CD46 bound
radiolabeled Ad3 with a dissociation constant of 0.3 nM, identical to that of CD46-positive HeLa cells
expressing twice as many Ad3 binding sites. Pull-down experiments with recombinant Ad3 fibers and a soluble
form of the CD46 extracellular domain linked to the Fc portion of human immunoglobulin G (CD46ex-Fc)
indicated direct interactions of the Ad3 fiber knob with CD46ex-Fc but not CARex-Fc (Fc-linked extracellular
domain of CAR). Ad3 colocalized with cell surface CD46 in both rodent and human cells at the light and
electron microscopy levels. Anti-CD46 antibodies and CD46ex-Fc inhibited Ad3 binding to CD46-expressing
BHK cells more than 10-fold and to human cells 2-fold. In CD46-expressing BHK cells, wild-type Ad3 and a
chimeric Ad consisting of the Ad5 capsid and the Ad3 fiber elicited dose-dependent cytopathic effects and
transgene expression, albeit less efficiently than in human cells. Together, our results show that all of the major
splice forms of CD46 are predominant and functional binding sites of Ad3 on CD46-expressing rodent and
human cells but may not be the sole receptor of species B Ads on human cells. These results have implications
for understanding viral pathogenesis and therapeutic gene delivery.
To date, 51 human adenovirus (Ad) serotypes have been
identified and classified into six species, A to F (47). The major
Ad vectors currently used in clinical applications are derived
from species C Ad serotype 2 (Ad2) and Ad5. Their biology is
very well characterized (for reviews, see references 27, 33, and
38). Species C entry into epithelial cells occurs after virus
binding to the coxsackie B virus-Ad receptor (CAR) (2), fol-
lowed by engagement of heterodimeric v-integrins as second-
ary receptors (49), which facilitate viral endocytosis and sig-
naling in target cells. Although species C Ads very efficiently
infect a number of cells and tissues, the lack of CAR or inte-
grin expression may limit their general usefulness for gene
therapy.
Unlike most serotypes of species A, C, D, E, and F Ads, the
species B Ads were suggested to bind to a different cell surface
receptor (6, 32, 43). The species B Ads cause a significant
number of infections worldwide. The B1 subspecies, including
Ad3, Ad7, Ad16, Ad21, and Ad50, predominantly infect the
upper respiratory tract, and the B2 subspecies, including Ad11,
Ad14, Ad34, and Ad35, infect the kidneys and the urinary tract
(48). Some species B Ads are capable of infecting cells refrac-
tory to the well-characterized species C Ads and have a low
seroprevalence (34, 46). These characteristics make the species
B Ads interesting vectors for gene therapy approaches (14).
We demonstrate here that the membrane cofactor CD46 is a
receptor for species B Ad3. Our data indicate that CD46 di-
rectly binds to the Ad3 fiber knob with subnanomolar affinity
and mediates dose-dependent viral transgene expression and
cytopathic effects (CPE) in rodent and human cells.
MATERIALS AND METHODS
Virus. The molecular identity of the Ad3 stock (prototype strain GB, kindly
provided by the late T. Adrian, Medizinische Hochschule Hannover, Hannover,
Germany) was verified by DNA restriction analysis (1) and DNA sequencing.
This Ad3 stock has a single point mutation in the fiber gene resulting in a
Tyr-to-Ser change at position 218 of the fiber head (Y218S), relative to the
published sequence (39). Ad3 was grown, isolated, radiolabeled, or fluorochrome
labeled as described for Ad2 (12, 30). CsCl-purified 3H-labeled Ad3 had a
specific radioactivity of 2.14  105 dpm/g. Purified virus was judged to be
homogeneous by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophore-
sis (PAGE) and negative-staining electron microscopy (EM) analyses. Alexa-
488- and Texas red (TR)-labeled Ad3 had the same infectivity as the unlabeled
parental virus.
Construction of Ad5-based AdCMV-eGFP, derived from an E1/E3 deletion
mutant, has been described elsewhere (28). The chimeric Ad3 fiber- Ad5-based
AdCMV-eGFP vector (Ad5/F3) was constructed in a manner similar to that
described for Ad5/F35 (37). Briefly, Ad5/F3 contained 45 amino acids of the Ad5
tail fused to 86 amino acids of the Ad3 shaft and 187 amino acids of the Ad3
knob by overlapping PCR (fiber swapping). The chimeric fragment was intro-
duced into transfer plasmid pBL-EcofrgAd5, containing 6,729 bp of the right end
of Ad5, including the fiber gene and inverted terminal repeat sequence, by using
the unique NdeI and AflII sites. The AdCMV-eGFP-5F3 chimeric virus was
generated by homologous recombination of EcofrgAd5/F3 with a pTG-H5dl324-
derived plasmid (4), which contained a cytomegalovirus (CMV)-enhanced green
fluorescent protein (eGFP) expression cassette in the E1 region and uniquely
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cutting restriction site SwaI inserted into the deleted fiber region. The resulting
construct, pTG-H5dl324-CMV-eGFP-5F3, was digested with PacI to release the
viral genome, which was rescued by transfection of helper 911 cells (9). CsCl
purification of Ad5-based AdCMV-eGFP and Ad5/F3 yielded 6  109 and 2.4 
108 PFU, respectively, with physical titers of 7.5 1011 and 1.6 1010 virions/ml,
respectively, as determined by previously described methods (15).
Cells and screening of the cDNA library. BHK-21 cells and all other cells were
grown as described previously (8, 19). For stable transfections, the CD46-encod-
ing cDNA clones 28 and 54 or, alternatively, the cDNA encoding CAR (2, 8) was
PCR amplified and cloned into pCDNA3 (Invitrogen). For bulk cultures, plates
containing 100 G418-resistant clones were trypsinized and enriched for CD46
expression by fluorescence-activated cell sorting on a MoFlo high-speed sorter
(Dako-Cytomation, Fort Collins, Colo.). Clonal lines were established by limiting
dilution of sorted bulk cultures of BHK cells expressing CD46 (BHK-CD46
cells)–clone 54 (BHK-CD46-cl54 bulk cells). Generation of the Sindbis virus
K562 cDNA library, sorting, reverse transcription-PCR, and sequencing were
performed as described earlier (19).
Immunoreagents and flow cytometry. Details for the anti-CD46 antibodies
used here are listed in Table 1. For cytofluorometric analysis, 2  105 cells were
incubated with 5 g of Ad3- Alexa-488, with 1 g of E4.3 antibody for CD46
detection, or with 1 g of E1-1 antibody for CAR detection as described previ-
ously (8). For eGFP expression analysis, triplicate samples of 2  105 cells were
infected at multiplicities of infection (MOIs) of 3.3, 10, and 30, washed at 2 h
postinfection (p.i.), and analyzed at 2 days p.i.
Binding isotherm and Scatchard plots. Subconfluent cells were detached in
phosphate-buffered saline- 20 mM EDTA and washed twice with RPMI medi-
um-0.2% bovine serum albumin (BSA). Triplicate samples of 5  105 cells were
incubated in 100 l of RPMI medium-BSA for 30 min at 37°C with or without 2
g of Ad3 dodecahedron fiber (DF). Note that Ad3 DF and the fiber head,
prepared as described previously (7, 10), had the wild-type sequence Y218 (P.
Fender, Grenoble, France, personal communication). Cold RPMI medium-BSA
with the appropriate amount of virus (1 part 3H-labeled Ad3 plus 9 parts Ad3)
was added to a final reaction volume of 200 l and allowed to react for 90 min.
Ad3 concentrations were based on an approximate molecular mass of 150 MDa
per particle. The cells were washed twice with RPMI medium-BSA and once with
Hanks’ balanced salt solution. Cell-associated radioactivity was measured as
described earlier (28). Regression analyses of binding data were performed with
Prism software (GraphPad Software Inc., San Diego, Calif.).
Blocking of Ad3 binding. Cells were detached with phosphate-buffered saline-
20 mM EDTA, and 2  105 cells were incubated with monoclonal and polyclonal
antibodies specific for CD46, anti-human CAR antibody E1-1 (8), soluble
CD46ex-Fc (comprising 295 amino acids of the mature extracellular domain
fused to 232 amino acids of the human immunoglobulin G1 (IgG1) Fc domain,
including the hinge, CH2, and CH3 regions), and CARex-Fc (8) or a 30-fold
excess of unlabeled Ad3 on ice for 15 min. Subsequently, 5 g of Ad3- Alexa-488
or 3H-labeled Ad3 was added in a total volume of 200 l on ice; after 1 h, the
cells were washed and analyzed for bound virus by cytofluorometry or liquid
scintillation counting (28). The data were normalized to the amounts of virus
bound in the absence of inhibitors and are presented as the mean of three
independent experiments and standard deviations. Statistical evaluation was
performed with Student’s t test. Experiments to assess CPE were carried out by
using microtiter plate assays with triplicate input samples. Serial 10-fold dilutions
of various virus stocks were plated in a volume of 50 l in a 96-well dish, starting
with a concentration of 6  105 viral particles/ml. All dilutions were prepared in
cell culture medium. Cells were diluted to 6.7  104/ml, and 150 l of this
suspension was added per well (MOIs ranged from 3 101 to 3 104). Attached
cells were fixed with methanol at 72 h p.i. and stained with crystal violet.
Microscopy. Confocal laser scanning microscopy (CLSM) was performed by
using a DM RXA2 TCS SP2 AOBS microscope (Leica Microsystems, Wetzlar,
Germany) equipped with an Ar or Ar-Kr laser, an He-Ne 543/594 laser, an
He-Ne 633 laser, a diode laser (405 nm), and a 63 oil immersion objective
(N.A. 1.4 PL APO). The pinhole value was 115 m, airy 1, yielding optical
sections of about 0.12 m, and the step size was set to 0.122 m with a voxel of
0.233 by 0.233 by 0.122 m. Image processing was performed with MetaMorph
(Universal Imaging Inc., Visitron Inc., Downingtown, Pa.) and Photoshop
(Adobe). Transmission EM was performed by using a modification of a previ-
ously described protocol (40). Briefly, Ad3 was cold bound to or internalized in
BHK-CD46-cl54 bulk cells as described previously (29, 44), and the specimens
were fixed in 2% paraformaldehyde (PFA)- 1.5% glutaraldehyde (GA) in 0.1 M
sodium cacodylate (pH 7.4) overnight, washed in fixative-free buffer, and post-
fixed in 1% osmium tetroxide (Electron Microscopy Sciences)- 1.5% potassium
ferricyanide at 4°C for 1 h. The specimens were rinsed in 0.1 M sodium caco-
dylate, contrasted with 1% tannic acid in 0.05 M sodium cacodylate at room
temperature for 45 min, washed in 1% sodium sulfate, rinsed in H2O, stained in
2% uranyl acetate in H2O overnight, and embedded in Epon. For preembedding
immunogold EM, cells were fixed in 0.2% GA- 2% PFA in 0.1 M sodium
cacodylate (pH 7.4) for 20 min, labeled with anti-CD46 antibodies (5 g/ml in
10% goat serum) for 1 h and goat anti-mouse IgG (5-nm gold; 10 g/ml; British
BioCell International) for 2 h, postfixed in 1.5% GA- 2% PFA, and further
processed as described above.
CD46ex-Fc pull-down assays. Ad3 DF and the dodedahedron penton (DP) of
Ad3 were centrifuged at 16,100  g for 10 min, and the fiber head and
CD46ex-Fc were centrifuged at 100,000  g for 30 min. CD46ex-Fc was incu-
bated with the respective viral proteins in a final volume of 50 l of binding buffer
(BB; 50 mM HEPES-KOH [pH 7.4], 0.5% Triton X-100, 150 mM NaCl, 1 mM
MgCl2, 0.1 mM CaCl2, 1 mM phenylmethylsulfonyl fluoride, 1 g each of chy-
mostatin, leupeptin, aprotinin, and pepstatin per ml, 0.1% BSA) for 1 h. The
ratio of binding partners was 1.1 g of CD46ex-Fc to 1 g of DF or DP and 3.3
g of CD46ex-Fc to 1 g of fiber head. A total of 450 l of BSA-free buffer and
20 l of a 1:1 slurry of protein G-Sepharose 4 Fast Flow (Amersham) were
added, and the mixture was incubated under constant agitation for 2 h. The
Sepharose beads were sedimented at 3,000  g for 2 min, washed twice with BB
without BSA, and washed twice with BB without BSA and Triton X-100. The
pellet was resuspended in 20 l of doubly concentrated reducing sample buffer
and boiled at 95°C for 5 min. A total of 15 l of the supernatant was separated
by SDS- 12% PAGE and silver stained at room temperature as described pre-
viously (16). All steps were carried out at 4°C unless indicated otherwise.
RESULTS
Isolation of CD46 cDNAs encoding the Ad3 receptor. To
identify a cell surface receptor(s) for species B1 Ads, we used
the Sindbis virus-based cDNA expression system (19) to screen
for the binding of Ad3 particles labeled with the fluorophore
Alexa-488 to BHK cells. The cDNA library was made from
human K562 chronic myelogenous leukemia cells, which effi-
ciently bound Ad3- Alexa-488 (Fig. 1A, left panel). In contrast,
rodent BHK cells did not bind significant amounts of Ad3, in
TABLE 1. Antibodies used for CD46 staining and blocking
Antibody Epitoperecognized Source
GB-24 SCR3/4 T. Seya, Osaka Medical Center, Osaka, Japan
M75 SCR2 J. Atkinson, Washington University, St. Louis, Mo.
E4.3 SCR1 Pharmingen Switzerland, Basel, Switzerland
MCI20.6 SCR1 D. Gerlier, Faculte´ Me´decine Lyon, Lyon, France
13/42 SCR1 BMA Biomedicals AG, Augst, Switzerland
Tra-2.10 SCR1 J. Atkinson
MEM-258 SCR4 Serotec Ltd., Oxford, United Kingdom
Rabbit anti-CD46 (amino acids 35–328) Not available Santa Cruz Biotechnology, Santa Cruz, Calif.
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agreement with the earlier notion that the receptor for species
B Ads is not conserved between rodents and primates (13, 14,
36) (Fig. 1A, right panel). About 0.0024% of Sindbis virus-
infected cells expressing cDNAs also bound fluorescent Ad3-
Alexa-488 (Fig. 1B), whereas cells infected with Sindbis virus
lacking cDNA inserts did not (Fig. 1C). Rescreening resulted
in more than 30 positive clones binding Ad3; one of these is
shown in Fig. 1D. Of 30 positive clones, 28 contained cDNA
fragments of about 3 kb encoding CD46; the other 2 clones
represented cloning artifacts. It is known that multiple splice
variants of the Ser/Thr-rich domain-encoding exons and cyto-
plasmic tail exons give rise to four major splice variants, C1,
C2, BC1, and BC2, and to additional minor variants (21).
Among the 10 inserts that were completely sequenced, the
major splice variants C2 and BC1 were found five times and
two times, respectively, and the variants BC2 and C1 were
found once each. The rare form B1 was found once, whereas
the rare forms ABC1 and ABC2, typically expressed in cancer
cells, were not recovered.
Ad3 binds with a high affinity to BHK-CD46 cells through
direct fiber head-CD46 interactions. BHK cells stably express-
ing the BC1 form (cDNA clone 54) were generated. CD46
expression levels of bulk cultures (BHK-CD46-cl54 bulk cells;
data not shown) or clonal BHK-CD46-cl54-A1 cells expressed
CD46 at intermediate levels, compared to human cell lines,
such as K562, HeLa, and A549 (Fig. 2A). The binding of
3H-thymidine-labeled Ad3 to BHK-CD46-cl54 bulk cells was
dose dependent and saturable, compared to background bind-
ing in the presence of 2 nM Ad3 DF (10) and to parental BHK
cells (Fig. 2B). One DF consists of 12 penton base pentamers,
each of which contains one trimeric fiber molecule with a distal
fiber head at the outside. Scatchard plots of Ad3 binding
showed parallel slopes with extrapolated Kd values of 0.3 nM
for both BHK-CD46 transfectants and HeLa cells (Fig. 2C).
The number of Ad3 binding sites on BHK-CD46-cl54 bulk
cells was 2.4  103, and that on human cervical carcinoma
HeLa cells was 4.4  103, consistent with earlier experiments
with human nasopharyngeal carcinoma KB cells and human
lung carcinoma A549 cells (6). Competition with the recombi-
nant Ad3 fiber knob (7) eliminated more than 75% of Ad3
binding to HeLa cells (mean of two experiments; data not
shown), in agreement with earlier experiments (43). Further,
CD46ex-Fc was able to pull down both the recombinant Ad3
fiber head and DF but not DP (Fig. 2D). DF was not recog-
nized by CARex-Fc, indicating specific binding of DF to
CD46ex-Fc (data not shown). In addition, CD46ex-Fc also
pulled down Ad3 but not Ad2 or the fiber head of Ad2, further
confirming the specificity of the interaction of CD46 with Ad3
(data not shown). These results indicate that CD46 expression
on nonpermissive rodent cells mediates high-affinity and satu-
rable Ad3 binding through a direct interaction of the extracel-
lular CD46 domain with the Ad3 fiber head.
Colocalization of Ad3 with CD46 during viral entry. We next
analyzed Ad3 interactions with BHK-CD46 cells and human
epithelial cells (HeLa cells) positive for CD46 and permissive
for Ad3 by light microscopy and EM. TR-labeled Ad3 bound
homogeneously to the cell surface at 4°C, and a large fraction
colocalized with CD46, as determined by indirect immunoflu-
orescence and single-section CLSM (Fig. 3A and 4A). Over-
FIG. 1. CD46-expressing cells bind Ad3. (A) Flow cytometry of human leukemia K562 cells and rodent BHK cells that were not incubated with
(white histograms) or that were incubated with (shaded histograms) Ad3- Alexa-488. (B and C) Single-cell sorting of BHK cells infected with
Sindbis virus expressing a K562 cDNA library (B) and control Sindbis virus (C) after staining with propidium iodide (PI), anti-Sindbis virus
antibodies (FL4), and Ad3- Alexa-488 (FL1). (D) PI-negative, Sindbis virus- and Ad3-positive cells (gate) were single cell sorted into 24-well plates
containing BHK feeder cells and rescreened for Ad3- Alexa-488 binding. One of 30 positive clones is shown.
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lapping staining of CD46 and staining of TR-labeled Ad3
was particularly prominent in basal and peripheral regions
of BHK-CD46 and HeLa cells, consistent with basolateral
surface expression of CD46 in certain polarized monkey and
human cell lines (23) and both apical and basolateral ex-
pression in differentiated human airway epithelial and tra-
cheal tissues (41). Ad3-CD46 colocalization was confirmed
by high-resolution indirect immunogold EM depicting gold
particles attached to goat anti-mouse IgG near Ad3 and
occasionally elsewhere on the cell surface (Fig. 3B and 4B).
No gold particles were observed in the absence of anti-CD46
antibodies (data not shown). Upon warming, Ad3 was found
in the cytosol and endosomal vesicles of BHK-CD46 cells,
partly colocalized with CD46 (Fig. 3A, e to g, and Fig. 3B,
b). Similar results were obtained with HeLa cells (Fig. 4A, d
to f).
FIG. 2. Ad3 binds with a high affinity to CD46-expressing cells through the fiber head. (A) Cytofluorometric analysis of CD46 expression levels
in human and hamster cell lines. White histograms show staining with isotype control antibodies, and shaded histograms show CD46-specific
staining. The cells used were human K562, HeLa, and A549 cells, parental BHK cells, and stably transfected BHK cells expressing the BC1 isoform
of CD46. (B) Binding isotherms of Ad3 incubated with BHK-CD46-cl54 bulk cells or parental BHK cells. Nonspecific binding was determined in
the presence of Ad3 DF. Error bar depicts standard error of the mean. (C) Scatchard analysis of Ad3 binding to BHK-CD46-cl54 bulk cells and
HeLa cells. The number of binding sites per cell and the Kd values were calculated from the bound and the free virion concentrations determined
by subtracting the bound virus from the input virus. (D) Direct interaction of the Ad3 fiber head with CD46ex-Fc. CD46ex-Fc was incubated
without any addition (lane 1), with the purified fiber head (lane 2), with DF (lane 3), and with DP (lane 4). CD46ex-Fc was pulled down by protein
G (Prot G)-Sepharose, and the SDS eluates were analyzed by SDS-PAGE and silver staining.
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FIG. 4. Ad3 colocalizes with cell surface CD46 of HeLa cells.
(A) CLSM analyses of TR-labeled Ad3 (red) and CD46 stained with
non-function-blocking antibody MCI20.6 (green). Single sections are
shown at 0 min (a to c) and at 45 min (d to f) p.i. Scale bar, 5 m.
(B) Transmission EM showing immunogold staining of CD46 at 0 min
p.i. Arrows indicate Ad3 associated with protein A-gold directed to
anti-CD46; the small arrow indicates a gold particle not associated with
Ad3. Scale bar, 200 nm.
FIG. 3. Ad3 colocalizes with cell surface CD46 of BHK-CD46-cl54-
bulk cells. (A) CLSM analyses of TR-labeled Ad3 (red) and CD46
stained with non-function-blocking antibody MCI20.6 (green). Single
sections were taken at 0 min (a to d) and at 5 min (e to h) p.i., including
4,6-diamidino-2-phenylindole (DAPI)-stained sections (d and h).
Scale bars, 5 m. (B) Transmission EM (TEM). (a) Immunogold
staining of CD46 at 0 min p.i. Large arrows indicate Ad3 associated
with protein A-gold directed to anti-CD46; the small arrow indicates a
gold particle not associated with Ad3. (b) Ad3 internalization at 0 min
p.i. Arrowheads indicate clusters of cytosolic Ad3; the small arrow
indicates endosomal Ad3. Scale bars, 200 nm.
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CD46 expression mediates binding, gene expression, and
CPE. We further tested whether Ad3 binding to BHK-CD46
cells was specific for CD46 by using eight different anti-CD46
antibodies (Table 1) and CD46ex-Fc. Six monoclonal antibod-
ies and one polyclonal antibody to CD46 strongly inhibited
either Ad3- Alexa-488 or 3H-labeled Ad3 binding at concen-
trations that gave saturating antibody binding to BHK-CD46
cells (Fig. 5, left panel, and data not shown). Monoclonal
antibodies M75, 13/42, and MEM-258, recognizing epitopes on
short consensus region (SCR) 1 (SCR1), SCR2, and SCR4,
blocked Ad3 binding by more than 90%. Antibodies GB-24,
E4.3, and Tra-2.10, directed to SCR1 and SCR3/4, inhibited
binding at intermediate levels of 85, 65, and 62%, respectively.
In contrast, antibody MCI20.6, recognizing an SCR1 epitope,
and anti-CAR antibody E1-1 had no significant effect on Ad3
binding. The soluble CD46ex-Fc protein inhibited binding in a
dose-dependent manner (data not shown), with a maximal
inhibition of 43%, whereas the CARex-Fc protein had no ef-
fect. The specificity of this assay was further confirmed by
including a 30-fold excess of cold Ad3, reducing labeled Ad3
binding by 96%. The anti-CD46 antibodies also inhibited
Ad3 binding to K562 cells, albeit to a lesser extent than to
BHK-CD46 cells (Fig. 5, right panel). Notably, antibodies
M75, 13/42, and MEM-258, which were the most effective
blockers of Ad3 binding to BHK-CD46 cells, also conferred
maximal blocking in K562 cells amounting to about 40%. The
use of a mixture of all seven blocking antibodies did not in-
crease the blocking of Ad3 binding (data not shown). Likewise,
CD46ex-Fc did not inhibit Ad3 binding to K562 cells and,
surprisingly, somewhat enhanced Ad3 binding (data not
shown). This result may be related to the capacity of
CD46ex-Fc to form dimers, but additional experiments are
required to clarify this observation.
We next measured Ad3-mediated gene delivery to BHK-
CD46 transfectants by using Ad5/F3 (Fig. 6A). Ad5/F3-medi-
ated eGFP expression in hematopoietic human K562 and
THP-1 cells was 10- to 20-fold higher than eGFP expression
from an Ad5 vector, confirming the functionality of Ad5/F3.
This finding was in agreement with earlier reports (42). In
BHK-CD46-cl54-A1 cells, the eGFP expression of Ad5/F3 in-
creased in a dose-dependent manner to a maximum of 16-fold,
compared to that in BHK cells and CAR-expressing BHK cells
(BHK-CAR cells). In BHK-CD46-cl28 bulk cells (an addi-
tional BC1 cDNA clone) and clone 54 cells, expression in-
creased to an intermediate level of sevenfold (data not shown),
correlating with a twofold-lower level of CD46 expression in
these cells than in BHK-CD46-cl54-A1 cells. The transgene
expression of Ad5/F3 in human A549 cells was about 30-fold
higher than that in clonal BHK-CD46 cells. As expected, BHK
and BHK-CD46 transfectants remained refractory to Ad5-me-
diated eGFP expression, whereas eGFP expression from Ad5
in stable BHK-CAR cells was increased about 23-fold, com-
pared to a 300-fold increase in A549 cells.
We next measured the CPE of Ad3 in BHK-CD46 cells and
found that there is about a 1-log-unit increase in the sensitivity
of BHK-CD46 cells over that of native BHK cells (Fig. 6B).
Control infections with Ad5 showed no difference in CPE
between BHK and BHK-CD46 cells. Human cells were up to
2 log units more sensitive to Ad5 and at least 1 log unit more
sensitive to Ad3 than BHK-CAR or BHK-CD46 cells to Ad5
or Ad3, respectively (Fig. 6B), consistent with the eGFP ex-
pression data for Ad5/F3 (Fig. 6A). Together, these experi-
ments corroborate the binding data and demonstrate that pa-
rental BHK cells are refractory to Ad3 infection, whereas
BHK-CD46 transfectants develop Ad3-mediated CPE, imply-
ing that CD46 supports Ad3 infection.
FIG. 5. CD46-dependent binding of Ad3 revealed by anti-CD46 antibodies and CD46ex-Fc. BHK-CD46-cl54 bulk cells and human K562 cells
were incubated with the indicated antibodies, CD46ex-Fc, or CARex-Fc (control), followed by the addition of either Ad3- Alexa-488 or 3H-labeled
Ad3. Virus binding was measured by flow cytometry or liquid scintillation counting. The asterisks indicate the level of significance (P values of
0.05 [single asterisks] and 0.005 [double asterisks] for comparisons with the negative controls E1-1 [anti-CAR] and CARex-Fc, respectively).
rab, rabbit.
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DISCUSSION
Our expression cloning approach identified a receptor of
species B Ad3, the membrane cofactor CD46. The screening
experiments indicated that all four major splice variants, BC1,
BC2, C1, and C2, and the rare splice form B1 are capable of
binding Ad3, similar to what has been described for the bind-
ing of measles virus (24). Ad3 binding to rodent cells express-
ing the most common isoform, BC1, was of high affinity and
saturable; the yield was about 2,400 virus binding sites per
rodent cell, compared to 4,400 per HeLa cell, consistent with a
previous report on HeLa cells (6). We found that Ad3 binding
to CD46-expressing rodent cells was inhibited by a panel of
anti-CD46 monoclonal and polyclonal antibodies and by a
recombinant extracellular domain of CD46, supporting the
notion that CD46 represents a major Ad3 binding site in these
cells. In human cells, CD46 is also an important Ad3 receptor,
as indicated by colocalization data at the light microscopy and
EM levels and by antibody inhibition experiments, although
the latter were less efficient than those with rodent cells. Note-
ably, Ad3 has the same subnanomolar affinity for BHK-CD46
cells as for HeLa cells and enters and gives rise to transgene
expression and CPE in both cell types. Further, in vitro pull-
down experiments indicated that Ad3 directly binds the extra-
cellular domain of CD46 through contact with the fiber head.
Nonetheless, a recent study had suggested that a particular
Ad3 isolate did not bind to Chinese hamster ovary cells ex-
pressing the C2 isoform of CD46 (11). We therefore checked
the DNA sequence of our Ad3 stock and found that the fiber
sequence was identical to the published sequence (39), except
for a point mutation (Y218S) in the fiber head. This mutation,
however, is unlikely to affect virus binding to CD46, since the
recombinant Y218 fiber directly bound to CD46ex-Fc (like our
Y218S Ad3) and Y218 DF abolished the binding of our Ad3 to
HeLa and BHK-CD46 cells as efficiently as nonlabeled com-
petitor Y218S Ad3. These data strongly argue that all of the
splice variants of CD46 can serve as Ad3 binding sites, at least
on rodent cells. However, Ad5/F3-mediated gene expression
and wild-type Ad3-mediated CPE in rodent cells were lower
than those in human epithelial cells (A549 and HeLa cells).
Similarly, Ad5-mediated eGFP expression was lower in BHK-
CAR cells than in fully permissive A549 cells. It is unknown
whether rodent cells lack an unidentified factor for effective
Ad-mediated transgene expression, for example, a secondary
receptor stimulating endocytosis and nuclear transport (26,
45). It is interesting, however, that the level of Ad3 infection
was reduced about threefold in human M21-L12 cells lacking
v	3- and v	5-integrins compared to integrin-positive
M21-L4 cells and that infection of M21-L4 cells was inhibited
by integrin-specific antibodies and RGD peptides blocking
penton base interactions with integrins (25). Whether the as-
sociation of CD46 with 1-integrins, as reported for HeLa cells
(22), facilitates Ad3 infection needs to be investigated. It is
FIG. 6. Transgene expression by chimeric Ad5/F3 and CPE of wild-type Ad3 in BHK-CD46 cells. (A) Ad-mediated eGFP expression in
permissive human cells and CD46- or CAR-transfected rodent cells. The indicated cells were incubated with eGFP-expressing Ad5 or Ad5/F3 at
different MOIs, and eGFP expression was analyzed at 2 days p.i. by flow cytometry. Results are shown as the mean fluorescence intensity (MFI).
(B) CPE of wild-type Ad3 in CD46-transfected BHK cells and human HeLa cells and control infections of BHK-CD46 and HeLa cells with
eGFP-expressing Ad5. Cells were infected with 10-fold dilutions of virus (3  101 to 3  104 particles/cell) for 3 days, fixed with methanol, and
stained with crystal violet.
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possible that human cells express additional Ad3 receptors
unrelated to CD46, as suggested by our finding of relatively
weak Ad3 binding inhibition with anti-CD46 antibodies in
K562 cells. The nature of such hypothetical binding sites is
unclear. It is also conceivable that glycosylation may modulate
Ad3 binding. Interestingly, CD46 is heavily N and O glycosy-
lated, depending on the tissue type, and the removal of N-
linked but not O-linked glycans or sialic acid abolished the
binding of measles virus strain Edmonston, which also uses
CD46 as a receptor (17).
In terms of CD46 binding and infection, it appears that our
Ad3 behaves more like species B Ad11 and Ad35 than Ad7.
The binding of both Ad3 and Ad11 to human cells was partially
blocked by anti-CD46 antibodies, with 20 to 30% inhibition for
Ad11 (35) and about 40% inhibition for Ad3 (this study), or by
small interfering CD46 RNAs, which reduced Ad35 binding by
about 40% (11). The soluble CD46 receptor also inhibited the
transgene expression of Ad5/F35 (11). The binding of Ad7 to
human cells was apparently unaffected by anti-CD46 antibod-
ies (35). In contrast, Ad3, Ad7, and Ad11 binding to CD46-
expressing rodent cells was inhibited by anti-CD46 antibodies,
and infection of CD46 BC1 isoform-expressing Chinese ham-
ster ovary cells was possible with Ad11 but not with Ad7; these
results suggested that Ad7 may bind CD46 but not use it for
infection. It is unknown, however, whether Ad7 infects human
cells with the same efficiency as CD46-expressing rodent cells.
Whether Ad3, Ad7, Ad11, Ad35, and other Ad serotypes all
use the same binding site on CD46 remains to be investigated.
The species B Ads are considerable human pathogens. Ad3
and Ad7 are responsible for a significant proportion of Ad
infections worldwide and cause infections of the upper respi-
ratory tract, including acute febrile and severe respiratory ill-
ness, whereas the less abundant Ad11 and Ad35 cause infec-
tions of the urinary tract (34). The identification of Ad3
receptor CD46 has medical implications for the development
of new antiviral agents. Besides, species B Ads are interesting
gene transfer vehicles, as they use a receptor distinct from the
common Ad receptor CAR. Since CAR is expressed on many
but not all cell types and is down regulated on many cancer
cells, conventional therapeutic Ad vectors have limitations.
These limitations can be overcome in part by swapping the
fiber protein of species C serotypes with that of species B
serotypes. Accordingly, fiber-swapped Ad vectors have an ex-
tended tropism compared to species C vectors and are able to
efficiently infect hematopoietic and dendritic cells (13, 14, 18,
31, 37). In addition, several species B Ads have a low sero-
prevalence, which makes them attractive for in vivo applica-
tions (46).
Ad3 adds to a growing list of pathogens binding to CD46.
For example, CD46 is known to be a receptor for measles virus
strain Edmonston, human herpesvirus 6, Neisseria gonorrhoeae,
N. meningitidis, Helicobacter pylori, and Streptococcus pyogenes
(reviewed in reference 20). CD46 belongs to a family of com-
plement activation regulators (21). The biological role of CD46
is to prevent complement activation on autologous tissue by
binding C3b and C4b and by acting simultaneously as a cofac-
tor for proteolytic factor 1. CD46 consists of four amino-ter-
minal SCRs of 60 amino acids each, one to three Ser/Thr-rich
domains, a short region of unknown function, one transmem-
brane domain, and a cytoplasmic tail. The antibody blocking
data suggest that Ad3 may bind to all four SCR domains, a
suggestion which would be in agreement with the finding that
three different receptors of the complement activation regula-
tor family (CD21, CD55, and CD46) can recognize viral par-
ticles through two or more SCR domains (for a review, see
reference 3). The first two SCR domains of CD46 are trimers
(3), indicating that CD46 would be well suited for tight inter-
actions with a trimeric ligand, such as the Ad3 fiber (5). To-
gether with evidence from recent reports suggesting that CD46
is a receptor for species B Ad11 and Ad35 (11, 35), our data
corroborate the notion that CD46 is a common receptor for
species B Ads. Given that CD46 is expressed on all human cells
except for erythrocytes, we expect that viruses using CD46 as a
receptor might have evolved broad infectivity tropism, allowing
them to utilize cells and infection pathways that are not acces-
sible to other Ad serotypes.
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